Font Size: a A A

The Relationship Between Post-neoadjuvant Chemotherapy Lymphocytic Infiltration In Residual Cancer And Prognosis In Breast Cancer Patients: A Meta-analysis

Posted on:2020-01-03Degree:MasterType:Thesis
Country:ChinaCandidate:M ZhangFull Text:PDF
GTID:2404330590980222Subject:Clinical medicine
Abstract/Summary:PDF Full Text Request
Background:Tumor infiltrating lymphocytes(TILs)are associated with the treatment and prognosis of breast cancer.However,whether TILs in residual breast tumors after neoadjuvant chemotherapy(NACT)is associated with prognosis requires further clarification.This study evaluated the relationship between post-neoadjuvant chemotherapy lymphocytic infiltration and the prognosis of breast cancer patients systematically,and provided a scientific basis for the treatment and prognosis of breast cancer.Methods:Pubmed,Embase,Cochrane Library,Web of Science,National Knowledge Infrastructure and Wanfang Database were searched for collecting post-neoadjuvant chemotherapy lymphocytic infiltration and breast cancer related literatures before March 1,2019.Hazard ratio(HR),95%confidence interval(95% CI),disease-free survival(DFS),recurrence-free survival(RFS),Metastasis-free survival(MFS)and overall survival(OS)were pooled in the meta-analysis.Then use RevMan 5.3 and Stata12.0 software to perform Meta-analysis.Results:11 studies were included in the meta-analysis with a total of breast cancer 945 patients.The results of meta-analysis showed that,for post-neoadjuvant chemotherapy lymphocytic infiltration in residual cancer,the H-TILs had a better DFS/RFS/MFS than that of the L-TILs[HR=0.35,95% CI(0.19,0.65),P=0.0008].Further subgroup analysis showed that for TNBC and HER2(+),the DFS/RFS/MFS of H-TILs were better than those of L-TILs [HR=0.33,95% CI(0.23,0.48),P<0.00001;HR = 0.25,95% CI(0.10,0.66),P = 0.005].As for post-neoadjuvant chemotherapy lymphocytic infiltration in residual cancer of TNBC,the OS of H-TILs was significantly better than those of L-TILs[HR=0.39,95% CI(0.27,0.56),P<0.00001].Conclusion: The level of TILs in post-neoadjuvant residual tumors has an important prognostic value for breast cancer,especially for HER2(+)and TNBC,H-TILs tend to have better prognosis than L-TILs as respect to the lower risk of death and disease.Due to the limited number of studies,a lot of researches and statistics are still needed at this stage to verify the above conclusions.
Keywords/Search Tags:Tumor infiltrating lymphocytes, breast cancer, meta-analysis, neoadjuvant chemotherapy, residual cancer burden
PDF Full Text Request
Related items
The Meta-analysis Of The Relationship Between The Tumor Infiltrating Lymphocytes And The Curative Effect Of Neoadjuvant Chemotherapy In Breast Cancer
The Predictive Value Of Prognostic And Response To Neoadjuvant Chemotherapy Of Tumor Infiltrating Lymphocytes In In Patients With Breast Cancer
Establishment And Verification Of A Prediction Model For Lymph Node Metastasis In Early Breast Cancer And A Prognostic Model For Non-pCR Patients After Neoadjuvant Therapy
The Predictive Value Of Systemic Immunoinflammatory Index And Tumor-infiltrating Lymphocytes On The Efficacy Of Neoadjuvant Chemotherapy In Locally Advanced HER-2 Positive Breast Cancer
The Predictive Value Of Stroma Tumor-infiltrating Lymphocytes And PD-L1 In Patients With Triple Negative Breast Cancer Treated With Neoadjuvant Chemotherapy
Clinical Study Of Tumor-Infiltrating Lymphocytes In Breast Cancer After Neoadjuvant Therapy
Effect Of Neoadjuvant In Combination With Chemotherapy On Tumor-infiltrating Lymphocytes And PD-L1 Expression In HER2-overexpression Breast Cancer And Its Clinical Significance
Analysis Of Clinical Applicability Of Modified Residual Cancer Burden System In Evaluating The Pathological Response Of Breast Cancer After Neoadjuvant Treatment
Changes Of STILs And PD-L1 Before And After Neoadjuvant Chemotherapy And Its Relationship With DFS In Breast Cancer Patients
10 Effects Of Neoadjuvant Chemotherapy On The Expression Of Programmed Death Ligand-1 And Tumor Infiltrating Lymphocytes In Lung Cancer Tissues